Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

Alkermes plc (NASDAQ:ALKS) on Monday released topline results from the randomized double-blind treatment period of the ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Alkermes plc stands fourth on our list among the most ...

The appeal of a drug-patent dispute that allowed patent owner Alkermes PLC to keep $65.6 million in allegedly improper ...

Alkermes (ALKS) closed the last trading session at $30.28, gaining 1.5% over the past four weeks, but there could be plenty ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alkermes ( (ALKS) ) has shared an update.

This collaboration aligns the interests of Alkermes and Biogen in the successful development and commercialization of ALKS 8700 as an important potential treatment option for patients suffering ...

Alkermes says that after its 2020 “board-led transformation,” in which it “refreshed” 70% of its board, the company has improved its operations significantly. Related.